Streetbeat News

Regulatory

OCUL

Ocular Therapeutix has received FDA agreement under Special Protocol Assessment for its first pivotal clinical trial of OTX-TKI in Wet AMD.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:03 pm

SGEN

Seagen's proposed transaction with Pfizer is expected to close in late-2023 or early-2024, subject to closing conditions. The transaction is currently under review by the FTC and has recently received approval from the European Commission.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:03 pm

TRI

Thomson Reuters (TRI) has announced the launch of its Generative AI strategy, with the new technology being incorporated into its flagship product, Westlaw Precision. The updated product will be available in the US from November 15.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:34 am

CLGN

Collplant Biotechnologies has announced a US patent for its photocurable dermal filler product candidate, which is being developed for the aesthetics market.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:29 am

MNPR

Monopar Therapeutics has presented data at the 2023 Connective Tissue Oncology Society Annual Meeting showing that Camsirubicin, in an ongoing Phase 1b trial, has demonstrated tumor reduction benefits in patients with advanced soft tissue sarcoma.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:06 am

MRK

The FDA has approved Merck's KEYTRUDA in combination with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. This approval could potentially increase Merck's market share in the cancer treatment sector.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:52 am

CVX

XOM

Senate Majority Leader Schumer has urged the Federal Trade Commission (FTC) to investigate whether proposed oil and gas acquisitions by Exxon Mobil Corp. and Chevron Corp. could violate antitrust laws.

Portfolio Pulse from Charles Gross

November 01, 2023 | 10:51 am

IRIX

Iridex has announced that the Local Coverage Determination L39620 Micro-Invasive Glaucoma Surgery will likely limit the patient types for which WPS Government Health Administrator will reimburse Cyclophotocoagulation procedures after December 24, 2023. This decision by WPS, a Medicare Administrative Contractor, could impact the use of Iridex's Cyclo G6 Laser System and Probe Delivery Devices in ophthalmology.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:49 am

GOOG

META

AI experts Geoffrey Hinton and Yann LeCun, both known as 'Godfathers of AI', engaged in a debate on the risks of AI. Hinton, who left Google (NASDAQ:GOOG) (NASDAQ:GOOGL) to freely discuss the risks of AI, mocked LeCun's comments about open source AI, comparing it to open sourcing nuclear weapons. LeCun, who works for Meta Platforms Inc. (NASDAQ:META), defended AI's purpose to enhance human intelligence. The debate comes amid calls for AI regulation from tech leaders and the establishment of the US AI Safety Institute.

Portfolio Pulse from Rounak Jain

November 01, 2023 | 10:47 am

MRK

Merck's Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, an anti-PD-1 therapy, has met its key secondary endpoint of overall survival. Previously, the trial had met its primary endpoint of disease-free survival, reducing the risk of disease recurrence or death by 32% compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:37 am